These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36610262)

  • 1. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
    Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
    ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
    Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
    Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
    Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
    Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
    BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
    Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
    BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
    Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
    Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
    Dai J; Zheng H; Jin J; Cheng Y; Xu H
    Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
    Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
    Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.
    Chen X; Zhang H; Wang M; Liu H; Hu Y; Lin T; Chen H; Zhao M; Chen T; Li G; Yu J; Zhao L
    Front Immunol; 2022; 13():783695. PubMed ID: 35401534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Xu RH; Ajani JA; Moran D; Guerrero A; Li R; Pavese J; Matsangou M; Bhattacharya P; Ueno Y; Wang X; Shah MA
    Gastric Cancer; 2024 Sep; 27(5):1058-1068. PubMed ID: 38954176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
    de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
    BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
    Zheng Z; Guo Y; Zou CP
    Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression.
    Kwak Y; Kim TY; Nam SK; Hwang HJ; Han D; Oh HJ; Kong SH; Park DJ; Oh DY; Lee HJ; Im SA; Yang HK; Lee HS
    Oncologist; 2024 Sep; ():. PubMed ID: 39306800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
    Huo G; Liu W; Chen P
    BMC Cancer; 2023 Feb; 23(1):143. PubMed ID: 36765356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Gastric Cancer.
    Högner A; Moehler M
    Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer.
    Matsuishi A; Nakajima S; Saito M; Saito K; Fukai S; Tsumuraya H; Kanoda R; Kikuchi T; Nirei A; Kaneta A; Okayama H; Mimura K; Hanayama H; Sakamoto W; Momma T; Saze Z; Kono K
    Sci Rep; 2024 Aug; 14(1):17916. PubMed ID: 39095563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.